Medicure Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Albert Friesen

Algemeen directeur

CA$232.2k

Totale compensatie

Percentage CEO-salaris	93.0%
Dienstverband CEO	27.2yrs
Eigendom CEO	22.7%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	19yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Albert Friesen's beloning veranderd ten opzichte van Medicure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$3m
Mar 31 2024	n/a	n/a	-CA$1m
Dec 31 2023	CA$232k	CA$216k	-CA$922k
Sep 30 2023	n/a	n/a	CA$1m
Jun 30 2023	n/a	n/a	CA$2m
Mar 31 2023	n/a	n/a	CA$1m
Dec 31 2022	CA$238k	CA$216k	CA$1m
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$760k
Mar 31 2022	n/a	n/a	CA$803k
Dec 31 2021	CA$324k	CA$302k	-CA$727k
Sep 30 2021	n/a	n/a	-CA$7m
Jun 30 2021	n/a	n/a	-CA$7m
Mar 31 2021	n/a	n/a	-CA$6m
Dec 31 2020	CA$331k	CA$331k	-CA$7m
Sep 30 2020	n/a	n/a	-CA$18m
Jun 30 2020	n/a	n/a	-CA$18m
Mar 31 2020	n/a	n/a	-CA$18m
Dec 31 2019	CA$347k	CA$331k	-CA$20m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$189k
Dec 31 2018	CA$315k	CA$315k	CA$4m
Sep 30 2018	n/a	n/a	CA$10m
Jun 30 2018	n/a	n/a	CA$12m
Mar 31 2018	n/a	n/a	CA$12m
Dec 31 2017	CA$440k	CA$315k	CA$11m

Compensatie versus markt: De totale vergoeding ($USD 166.08K ) Albert } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Albert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Albert Friesen (77 yo)

27.2yrs

Tenure

CA$232,200

Compensatie

Dr. Albert David Friesen, Ph.D. serves as Chief Executive Officer and Corporate Secretary and Director at Buffalo Capital Inc. Dr. Friesen serves as Chief Executive Officer at Canam Bioresearch Inc. Dr. Fr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Albert Friesen	Founder	no data	CA$232.20k	22.67% € 1.5m
Neil Owens	President & COO	5.4yrs	CA$220.38k	0.061% € 3.9k
Haaris Uddin	Chief Financial Officer	2.4yrs	CA$128.20k	geen gegevens
Reuben Saba	Vice President of Scientific & Medical Affairs	5.3yrs	CA$151.00k	geen gegevens

5.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van NGQ1 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Albert Friesen	Founder	27.2yrs	CA$232.20k	22.67% € 1.5m
Arnold Naimark	Independent Director	24.8yrs	CA$15.00k	0.81% € 51.6k
Peter Quick	Independent Director	19yrs	CA$10.00k	0.70% € 44.9k
Jeffrey Weitz	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Pierre Theroux	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Morris Karmazyn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stephen Hanessian	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Armstrong	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Trevor Hassell	Member of Scientific Advisory Board	no data	geen gegevens	0.020% € 1.3k
A. Lincoff	Member of Scientific Advisory Board	18.9yrs	geen gegevens	geen gegevens
Brent Fawkes	Independent Director	11.8yrs	CA$15.00k	0.55% € 35.2k
James Kinley	Director	2.4yrs	CA$10.00k	0.45% € 28.9k

19.0yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NGQ1 zijn ervaren en ervaren (gemiddelde ambtstermijn van 19 jaar).

Medicure Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors

Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director

Medicure Inc., Annual General Meeting, May 28, 2024

Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Insufficient new directors

Medicure Inc. Appoints James Kinley as Director

Recent updates

Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors

Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024

Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)

Now 26% undervalued after recent price drop

Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director

First quarter 2024 earnings released

Now 26% undervalued after recent price drop

Now 25% undervalued after recent price drop

Medicure Inc., Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)

Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 29%

Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)

Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)

Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)

Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)

Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022

Insufficient new directors

Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)

Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022

Medicure Inc. Appoints James Kinley as Director

Investor sentiment improved over the past week

First quarter 2022 earnings released

Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022

Full year 2021 earnings released: CA$0.07 loss per share (vs CA$0.64 loss in FY 2020)

Insufficient new directors

Medicure Inc., Annual General Meeting, Jun 16, 2022

Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of Americans

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)

CFO & Secretary has left the company

First quarter 2021 earnings released

Full year 2020 earnings released

New 90-day high: €1.10

Medicure Announces Early Completion of Enrollment for iSPASM

New 90-day high: €0.88

New 90-day high: €0.69

New 90-day low: €0.49

Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: €0.51

New 90-day low: €0.59

New 90-day high - €0.78

First half earnings released

Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020

Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd